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A genetical approach to deep venous thrombosis
Derin ven trombozuna genetik yaklaşım
Celal Yavuz
Medical School of Dicle University, Department of Cardiovascular Surgery, Diyarbakir, Turkey
ÖZET
Derin ven trombozu (DVT) sıklıkla cerrahi girişimler ve 
travma sonrası ve kanser veya immobilizasyon koşulla-
rının varlığında oluşur yaygın bir hastalıktır. Ancak aynı 
zamanda  bu  predispozan  faktörlerin  herhangi  biri  ol-
maksızın da gelişebilir. Bu durum araştırmacıları, orga-
nizmada  ki  trombotik  yatkınlığın  temelini  soruşturmaya 
yönlendirmektedir. Faktör V Leiden, Faktör II G20210 A, 
plazminojen aktivatör inhibitörü-1, protrombin A20210 ve 
faktör XIII-VIII yaygın protrombotik genetik mutasyonla-
rıdır. Bununla birlikte, mevcut çalışmalar trombotik olay-
ların sadece tek gen delesyonu veya hemstatik regülas-
yona bağlı olmadığını, diğer genetik risk faktörlerinden 
de etkilendiğini göstermektedir. Genetik mutasyonlarınn 
karmaşık etkileşimleri, trombotik sisteminin farklı düzey-
lerde etkiler veya hemostatik mekanizmaların birbirlerinin 
etkisini arttırabilir. Literatür analiziyle, klasik genetik fak-
törlerin ve yeni buluşların etki mekanizmalarının birlikte 
ele alınması, venöz trombozda genetik yatkınlık anlayışı-
mıza önemli katkıda bulunabilir.
Anahtar kelimeler: Derin ven trombozu, genetik yatkın-
lık, homeostatik mekanizmalar
ABSTRACT
Deep venous thrombosis (DVT) is a common disorder 
that  frequently  occurs  after  surgical  procedures  and 
trauma and in the presence of cancer or immobilization 
conditions. However, it can also develop without any of 
these  predisposing  factors.  This  condition  directs  the 
researcher’s enquiry to investigating the basis of organ-
ismal thrombotic predisposition. The common prothrom-
botic genetic mutations include factor V Leiden, factor II 
G20210 A, plasminogen activator inhibitor-1, prothrombin 
A20210, and factor XIII - VIII. Nevertheless, current stud-
ies suggest that the thrombotic events are not connected 
with single gene deletion or homeostatic regulation is also 
affected by other genetic risk factors. Complex interac-
tions of genetic mutations can be affects different levels of 
thrombotic system or reinforce each other’s effects on ho-
meostatic mechanisms. The analysis of literature, togeth-
er with the action mechanisms of the classic genetical 
factors and new suggestions, may contribute significantly 
to our understanding of the genetic predisposition to ve-
nous thrombosis. J Clin Exp Invest 2012; 3(2): 303-306
Key words: Venous thrombosis, genetic predisposition, 
homeostatic mechanisms
HAEMOSTATIC BALANCE AND VENOUS 
THROMBOSIS
Venous thrombosis usually involving the deep veins 
of lower extremity is a major worldwide health prob-
lem that causes significant mortality and morbidity 
rates.1,2 All steps of Virchow triad are important in 
etiology (Figure 1). However the main factor is de-
terioration of the homeostatic balance. The venous 
stasis and leukocyte adhesion to the endothelium 
triggers  the  coagulation  cascade.  Moreover  the 
clotting system must be activated. The basically fi-
brinolytic, anticoagulant and antiplatelet therapies 
aim to prevent the hypercoagulation.1,2
Factors  that  causes  the  disruption  of  coagu-
lation  cascade  in  favor  of  hypercoagulation;  anti-
thrombin-III,  protein-C  and  protein-S  deficiencies 
that leads to congenital hypercoagulation and ac-
quired hypercoagulation reasons such as oral con-
traceptives,  pregnancy,  malignancies,  nephrotic 
syndrome, systemic lupus erythematosus, surgical 
applications, immobilization etc.2-4 Congenital and 
acquired gene mutations may plays role in the for-
mation of thrombosis such as Factor V Leiden gene 
mutation.1,5C. Yavuz. A genetical approach to venous thrombosis 304
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Figure 1. Virchow triad
COMMON PROTHROMBOTIC GENES
Factor V
The common hereditary risk factor activated protein 
C (APC) resistance is firstly described by Dahlbäck 
et al in 1993.5 Bertina et al described genetical de-
fect that known as factor V Leiden mutation.6 The 
prevalence of this mutation was detected as 5%-6% 
in Europe.7
The active form of factor V plays an important 
role in the formation of thrombosis. APC prevents 
the formation of excessive thrombus by inactivating 
active form of factor V. Factor V Leiden mutation lo-
calized to one of the major points of APC departure. 
Because of this the negative-feedback mechanism 
is disrupted by APC resistance in this gene muta-
tion. APC resistance is responsible for the 20% of 
familial  venous  thromboses.  Surgical  applications 
and oral contraceptive usage is increases the fur-
ther venous thrombosis risk in individuals that car-
rying this mutation.6 Heterozygote form of this muta-
tion is increases the thrombosis risk 5-10 fold and this 
rates increases 80-100 folds according to general 
population in homozygote carriers.8
Prothrombin
Poort et al. firstly described the prothrombotic muta-
tion of prothrombin gene (the arrival of adenine in-
stead of guanine 20210th nucleotide in prothrombin 
gene) in 1996.9 This mutation is the second most 
common causes of hereditary thrombophilia.9,10 The 
plasma prothrombin concentration is increasing by 
about 30% by the reason of mutation and the ve-
nous thrombosis risk is increased when the plasma 
concentration of prothrombin level is exceeds 115 
IU/dL.10
Attia et al reported that the prothrombin gene 
mutation  can  be  leading  the  recurrent  venous 
thrombosis and it is more common in positive family 
history of DVT.11
Factor XIII
Factor XIII is a kind of transglutaminase that can 
detect  at  many  macrophages  and  monocytes  in 
plasma,  responsible  for  fibrin  cross-binding.  This 
enzyme exhibits high activity in homozygote muta-
tion of factor XIII V34L gene and it is activity mod-
erately increases in heterozygote mutation.12 How-
ever the change of valine-leucine in 34th position 
of factor XIII gene is protective effect against DVT 
with an unknown mechanism. Indeed, the factor XIII 
V34L gene mutation was observed more frequently 
in healthy control groups against DVT subjects.12 
β-Fibrinogen
β-Fibrinogen is a kind of plasma protein that plays 
an important role in tissue regeneration and coagu-
lation. Elevated fibrinogen levels may increases the 
DVT risk such as atherothrombosis. However, the 
mechanism of this situation cannot clarify with cur-
rent  evidences.  The  in-vitro  increased  fibrinogen 
levels do not increased the mortality and morbidity 
in animal models.13,14
The  most  common  G/A  polymorphism  have 
shown in the 455th area of fibrinogen gene. The 
presence  of A  allele  leads  to  increase  fibrinogen 
levels. Most of the studies cannot show any rela-
tionship between DVT and this gene mutation such 
as Renner et al. and Rasmussen et al.13,14
PAI-1
Plasminogen Activator Inhibitor 1 (PAI-1) also plays 
a role in fibrinolytic activity. PAI levels are increased 
by the reason of the 4G gene deletion in the 675th 
position  of  the  promoter  region  of  the  PAI  gene. 
Thus,  fibrinolytic  activity  is  deteriorated  and  the 
predisposition to thrombotic events is increased.15 
PAI-1 is an important physiological inhibitor of the 
tissue plasminogen activator and uroplasminogen 
activator in the modulation of fibrinolytic habits. So 
it acts variable roles in thrombotic events, such as 
coronary heart disease, deep-vein thrombosis, and 
obesity.16 Additionally, there are innumerable stud-
ies in the literature claiming an association between 
the 4G allele and the atherogenic lipid profile in dif-
ferent ethnicities.16 To sum up, prior studies show 
that combined or alone mutation of the PAI gene 
may cause the DVT.15
MTHFR
Current studies show that the hyperhomocystein-
emia due to the genetical defect in Methylenetet-
rahydrofolate reductase (MTHR) gene may cause 
atherosclerosis and vascular problems. These da-C. Yavuz. A genetical approach to venous thrombosis 305
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ta’s suggest that the T allele of the MTHFR C677T 
gene can reduced the plasma folate concentration 
and  increased  homocysteine  levels. At  the  other 
hand  plasma  homocysteine  level  is  highly  evalu-
ated in MTHFR A1298C gene mutation.17,18
There  are  different  opinions  in  the  MTHFR 
C677T v A1298C gene mutations which progress 
with highly homocysteine levels in DVT. Some re-
searchers  have  opposing  views  regarding  dele-
tions of this gene increases the risk of DVT. De-
spite controversial opinions, these mutations have 
been shown to increase susceptibility to thrombotic 
events.19,20
ACE
Renin-angiotensin system is a complex modulator 
of to blood pressure, homeostasis, cardiovascular 
remodeling, and vascular tone. his system consists 
of angiotensinogen, angiotensin converting enzyme 
(ACE),  angiotensin  II  and  key  proteins  which  in-
cludes homeostatic receptors . Angiotensin I con-
verted to the Angiotensin II through the endothelial 
ACE. Angiotensin II is stimulating PAI-1, which is 
responsible for down-regulation of the fibrinolysis.21
ACE,  reduces  fibrinolysis  and  increases  the 
thrombotic risk by reducing bradykinin which is an 
important mediator of tissue-type plasminogen (t-
PA).22 There are three genetical variations in ACE 
gene. There are three genotypic variations in ACE 
gene: DD, DI, and II. ACE levels are being highest 
in DD, intermediate in DI, and lowest in II.23 The 
studies which include various ethnic groups report-
ed that ACE DD gene deletion may be effective in 
venous thrombosis development.24
CONCLUSION
Current advances are focused on the genetical pre-
disposing factors in the cardiovascular events espe-
cially thrombotic disorders. The recent findings are 
concentrated for the improvement of the new treat-
ment and diagnostic strategies for these events.
To sum up, Prothrombotic gene mutations in-
crease the DVT risk with affected the coagulation 
factors by disrupts homeostasis in favor of coagula-
tion, directly or indirectly. The preventive and thera-
peutic methods for the DVT can be developed by 
clarifying the singled or combined effects of effects 
of  these  genes.  However,  collaborative  studies 
should be planned to reveal the systematic effects 
of these genes.
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